EDMONTON, AB , Jan. 26, 2023 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its second quarter fiscal year 2023 on Thursday, February 9, 2023 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results... Read More

EDMONTON, AB , Jan. 4, 2023 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that the Company has closed the sale of its Aurora Polaris facility for gross proceeds of approximately $15 million , previously announced to be closing under the Company's ongoing transformation program. Aurora's balance sheet... Read More

EDMONTON, AB , Dec. 9, 2022 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, is excited to announce its Greybeard Cannabis Co. brand has won KIND Magazine's 'Best Diamonds of the Year' award, as voted by hundreds of budtenders, store managers and independent cannabis retail owners across Canada . Greybeard is known for its... Read More

Balance Sheet Remains in Net Cash Position, Further Strengthened with Accretive Debt Reduction EDMONTON, AB , Dec. 5, 2022 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that it has repurchased an aggregate of approximately $102.5 million ( US$76.1 million ) principal amount of its convertible senior notes... Read More

NASDAQ | TSX: ACB EDMONTON, AB , Nov. 14, 2022 /CNW/ - Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the " Meeting ") held today, Monday, November 14, 2022 by virtual webcast. The total number of shares represented by... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its first quarter fiscal year 2023 on Thursday, November 10, 2022 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results for the first quarter fiscal year... Read More

Aurora medical patients now have expanded access to company's full portfolio of adult-use cannabis brands Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced a new and unprecedented fall lineup of cannabis products. New flower products include three unique and proprietary strains from Aurora's esteemed breeding program: Electric Honeydew , Ultra Grape... Read More

Balance Sheet Remains in Net Cash Position, Further Strengthened with Accretive Debt Reduction Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that it has repurchased an aggregate of approximately $31.3 million ( US$23.0 million ) principal amount of its convertible senior notes ("Notes") at a total cost, including... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and full fiscal year 2022 on Tuesday, September 20, 2022 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results for the fourth quarter and... Read More

Long Term Investment Expected to Deliver Aurora Immediate Positive Cash Flow Aurora acquires a controlling interest in Bevo; one of the largest suppliers of propagated vegetables and ornamental plants in North America with proven track record of profitability Bevo will continue to be run by existing management team; robust growth plan includes use of Aurora Sky for ornamental plant cultivation and for vegetable propagation... Read More

Aurora Further Strengthens Balance Sheet with Accretive Debt Reduction Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that it has repurchased an aggregate of approximately $25.3 million ( US$20 million ) principal amount of its convertible senior notes ("Notes") at a total cost, including accrued interest, of $24.3... Read More

Over-Allotment Option Exercised in Full Strengthened Balance Sheet Eliminates Need to Access the ATM Facility in the Near Future Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, has announced today the closing of its previously announced bought deal offering of units of the Company (the "Units") for gross proceeds of approximately... Read More

Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, has announced today that it has amended the terms of its previously announced bought deal financing. Under the amended terms, a syndicate of underwriters led by Canaccord Genuity and BMO Capital Markets, have agreed to buy on a bought deal basis 61.2 million units of the Company (the... Read More

Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today has announced today that it has entered into an agreement with a syndicate of underwriters led by Canaccord Genuity and BMO Capital Markets, under which the underwriters have agreed to buy on bought deal basis 51.1 million units of the Company (the "Units"), at a price of... Read More

State-of-the-art facility readying first delivery of medical grade cannabis for German patients Aurora Cannabis Inc . (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the company has received EU-GMP certification for its state-of-the-art medical cannabis production facility in Germany . As a leading manufacturer of medical cannabis... Read More

Increasing Original Target for Expense Savings; Management Now Expects $150 to $170 Million in Annualized Cost Savings by H1/2023 versus Stated Target of $60 to $80 Million Reiterating Adjusted EBITDA Profitability Run Rate by the End of Fiscal H1 2023 Remains #1 Canadian LP in High Margin Global Medical Cannabis Revenues; International Medical Revenue Increased 55% from Q3 2021 Strong balance sheet; Early Repurchase of... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora" ) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has completed its previously announced acquisition of TerraFarma Inc. (parent company of Thrive Cannabis) (" Thrive ") (the " Transaction ") for aggregate initial... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its third quarter fiscal year 2022 on Thursday, May 12, 2022 at 5:00 p.m. Eastern Time | 3:00 p.m.... Read More

Thrive's highly experienced and trusted cannabis team in craft cultivation, product innovation, and operational execution will lead Aurora's Canadian recreational business Expands Aurora's brand offering with Greybeard, an award-winning, super-premium, high margin brand regarded for its budtender appreciation Transaction is... Read More

Global Cannabis Net Revenue of $60.6 Million Adjusted EBITDA Improved by 22% to a loss of $9.0 Million versus Q1 2022 Company Reaffirms Goal of Adjusted EBITDA Profitability by H1/2023 Transformation Plan Ahead of Schedule; Company Now Expects to Realize Upper End of $60 to $80 Million Range in Total Cost Savings by H1/2023;... Read More

• Believed to be the largest shipment of medical cannabis to Israel to-date • Aurora continues to advance strategic leadership in the global cannabinoid industry Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the... Read More

Newly created directorship to be filled by Chitwant Kohli, Senior Financial Executive Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the appointment of Chitwant Kohli to the Company's Board of Directors (the "Board"), effective today. This is a newly added position that expands the Board to nine members, seven... Read More

Licensing deal set to assist in the advancement of research and development for cannabinoid biosynthesis Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora"), the Canadian company defining the future of cannabinoids worldwide, together with 22nd Century Group, Inc. (NASDAQ: XXII) ("22nd Century") announced today a... Read More

Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, is pleased to acknowledge the Company's increased ranking in The Globe and Mail's 2021 annual Report on Business review of Corporate Boards, known as Board Games. As recognized in... Read More

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced a renewed sponsorship of Cannabis Amnesty in support of their advocacy work, calling for blanket pardons to all individuals for the offence of simple possession of cannabis. The sponsorship will... Read More

Genetics and licensing business will be led by new hire, Casey Whelan , VP, Genetics Business Development Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced the naming of the Company's new genetics licensing business... Read More

Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB) the Canadian company defining the future of cannabinoids worldwide, is pleased to announce the voting results from its Annual General Meeting of Shareholders (the " Meeting ") held on Friday, November 12, 2021 by virtual webcast. The total number of... Read More

Transformation Plan On Track; Actions Taken-to-Date Have Driven Over $33 Million in Annualized Run-Rate Cost Savings Total Cannabis Net Revenue, Net of Provisions, Grew ~10% to $60.1 million Compared to $54.8 Million in Q4 2021 Adjusted EBITDA Excluding Restructuring Costs Improved by $4.0 million to a loss of $11.5 million... Read More

First Federally Regulated Recreational Market in Europe and Largest Outside of Canada Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that Aurora Nederland B.V., a wholly owned indirect subsidiary of the Company,... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its first quarter fiscal year 2022 on Tuesday, November 9, 2021 at 5:00 p.m. Eastern Time | 3:00 p.m.... Read More

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced a New Acre Project sponsorship to support ALUS. The commitment is intended to fund environmental programs in the communities where Aurora facilities are located. The sponsorship creates shared... Read More

Bidiol is the only full-spectrum cannabis oil that is fully produced domestically Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, has launched Bidiol, the first medical cannabis oil in Uruguay that is wholly produced domestically. The CBD oil is available in 3%... Read More

#1 Canadian LP in Global Medical Cannabis; Total Medical Cannabis Net Revenue Rose 9% Compared to Prior Year; Strong Adjusted Gross Margin before FVA of 68% Business Transformation Plan on Track; Reiterates Annual Cost Savings of $60 Million to $80 Million , Providing Clear Pathway to Adjusted EBITDA Profitability Balance Sheet Remains Strong with $440.9 Million of Cash at June 30, 2021 ; Working Capital Improves by $404.3... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has rescheduled its conference call to discuss the results for its fourth quarter and full fiscal year 2021 to Monday, September 27, 2021 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results for the fourth quarter... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and full fiscal year 2021 on Tuesday, September 21, 2021 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results for the fourth quarter and... Read More

Distinguished senior healthcare executive, Theresa Firestone , to fill newly added position Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the appointment of Theresa Firestone to the Company's Board of Directors (the "Board"), effective today. This is a newly created directorship that expands the Board to nine... Read More

Shipment is part of the Company's strategy to advance its leadership in the global cannabinoid space Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the delivery of a cannabis shipment worth nearly C$8 million , in one of the largest single shipments of cannabis that Israel has received. The sale is a significant... Read More

First ever adult-use cultivars Aurora has commercialized from Aurora Coast R&D facility Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the launch of three new proprietary cultivars under the Company's premium adult-use cannabis brand San Rafael '71: Stonefruit Sunset, Lemon Rocket and Driftwood Diesel. Guided by consumer insights to identify... Read More

Full Repayment of Credit Facility Results in Principal and Interest Savings of ~$25 Million In the Next Year Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has completed the restructuring of its balance... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that management will participate in three upcoming investor conferences. From June 1 -2, 2021 , Miguel Martin , CEO and Glen Ibbott , CFO will participate in the Jefferies Virtual Healthcare Conference. The Company will host virtual one-on-one investor meetings. On... Read More

The Company's patented technology expected to be key to commercial success in cannabinoid biosynthesis Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the launch of a dedicated Science & Innovation business group, with the aim of commercializing... Read More

Aurora Cannabis Inc. (the " Company " or " Aurora ") (NASDAQ | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced that it has completed the transfer of its stock exchange listing to The Nasdaq Global Select Market ("Nasdaq") from the New York Stock Exchange ("NYSE") after the market close today. The Company's common stock will begin trading as a Nasdaq-listed security at market open on... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, has filed a prospectus supplement establishing a new at-the-market equity program (the "ATM Program") that allows the Company to issue and sell up to U.S. $300 million of common shares in the capital of the Company (the "Common Shares") from treasury to the public, from time to time, at... Read More

Aurora Germany GmbH, a subsidiary of Aurora Cannabis Inc. (the " Company " or " Aurora ") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, and Grow Group PLC ("Grow"), a biopharmaceutical company focused on improving access to cannabis-based medicines in the United Kingdom ("UK"), today announced the extension of their long-standing strategic relationship by signing a two-year... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that the Company will be participating at the BMO Capital Markets 16 th Annual Farm to Market Virtual Conference. Chief Executive Officer, Miguel Martin , and Chief Financial Officer, Glen Ibbott , will be conducting virtual one-on-one meetings with investors throughout... Read More

Domestic Medical Net Revenue Steady at $26.9 Million Strong International Medical Net Revenue of $9.4 Million Total Cannabis Net Revenue, Excluding Provisions, of $58.4 Million Business Transformation Plan Continues, Management Expects to Deliver Incremental Cost-Saving Measures of $60 Million to $80 Million Annually Balance Sheet Remains Strong with ~$525 Million of Cash on Hand at May 12, 2021 Lead Independent Director... Read More

NYSE | TSX: ACB EDMONTON, AB , April 30, 2021 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its third quarter fiscal year 2021 on Thursday, May 13, 2021 at 5:00 p.m. Eastern Time . Miguel Martin , Chief Executive Officer, and Glen Ibbott ,... Read More

Aurora Cannabis Inc. (the " Company " or " Aurora ") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has filed a new preliminary short form base shelf prospectus (the "Base Shelf Prospectus") with securities regulators in each of the provinces of Canada , except Quebec , and a corresponding shelf registration statement on Form F–10 (the "Registration Statement")... Read More

Total Cannabis Net Revenue of $70.3 Million , Excluding Provisions of $2.7 Million , Up 11% over Q2 2020 Medical Cannabis Net Revenue of $38.9 Million , Up 42% Versus Q2 2020, Driven by a 562% Increase in High Margin International Medical Sales Adjusted EBITDA Loss, excluding Provisions and Termination Costs, of $12.1 Million Represents an Improvement of $53.1 Million Over Q2 2020; Current Loss Triggered by Several Decisions... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ABC) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call on Thursday, February 11, 2021 at 5:00 p.m. Eastern Time to discuss the results for its fiscal year 2021 second quarter ended December 31, 2020 . Miguel Martin , Chief Executive Officer, and Glen Ibbott , Chief Financial Officer,... Read More

Broadest Medical Cannabis Product Range in Australian Market Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has entered into a strategic agreement with MedReleaf Australia ("MedReleaf"). The companies have signed a five-year supply agreement, which provides for MedReleaf to act as the exclusive supplier in... Read More

Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the "Offering") of units of the Company (the "Units") for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold... Read More

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to... Read More